ROCKET PHARMACEUTICALS, INC. RCKTW
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-10.24
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$223.1M | — | -$190.5M | $277.2M |
| 2024 | $0 | -$258.7M | — | -$215.6M | $463.2M |
| 2023 | $0 | -$245.6M | — | -$211.4M | $492.6M |
| 2022 | $0 | -$221.9M | — | -$186.5M | $489.7M |
| 2021 | $0 | -$169.1M | — | -$128.8M | $454.7M |
| 2020 | $0 | -$139.7M | — | -$95.2M | $503.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Shah Gaurav | CEO | 2026-05-21 | Option exercise | 76,490 | $1.69 |
| Shah Gaurav | CEO | 2026-05-21 | Sell | 55,684 | $3.09 |
| Shah Gaurav | CEO | 2026-05-19 | Sell | 2,409 | $3.01 |
| Wilson Martin | General Counsel | 2026-05-19 | Sell | 662 | $3.01 |
| Militello John | See Remarks | 2026-05-19 | Sell | 384 | $3.01 |
| Wilson Martin | General Counsel | 2026-05-13 | Sell | 3,361 | $3.61 |
| Shah Gaurav | CEO | 2026-05-13 | Sell | 2,728 | $3.61 |
| Militello John | See Remarks | 2026-05-13 | Sell | 855 | $3.61 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.24 (distress)
- Working capital / assets 0.492
- Retained earnings / assets -4.361
- EBIT / assets -0.701
- Equity / liabilities 5.208
Source: SEC EDGAR filings · CIK 0001281895 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.